AnGes

AnGes MG, Inc. is a biopharmaceutical company with a mission to provide patients, especially those suffering from disease.

AnGes MG, Inc. is a biopharmaceutical company with a mission to provide patients, especially those suffering from disease for which no effective therapy has been available to date, with innovative drugs. AnGes focuses on development of gene medicine, a next-generation biopharmaceutical. AnGes MG, Inc. was founded in December 1999 on an innovative discovery by researchers at Osaka University. AnGes already went through the first stage of research and development and is now in the second stage of commercialization. “Naglazyme,” a drug for the treatment of mucopolysaccharidosis VI, an intractable disease, has already been marketed in Japan and HGF Plasmid (gene therapy) for the treatment of critical limb ischemia, which is a serious impairment of blood circulation in the legs, is in the last stage of clinical development. Development of “NF-κB decoy oligonucleotide,” a nucleic acid medicine that suppresses various types of inflammation including atopic dermatitis, disc degeneration, and medical device for prevention of vascular restenosis is also under way. Having started from research and development and now embarking on the new stage of practical application, AnGes strives to fulfill the expectations of patients, their families, shareholders, investors and the general public waiting for new drugs to be available and aims at becoming a “global leader in the field of gene medicine.”